Analyst Ratings For STML – StemlineTherapeutics (NASDAQ:STML)
Today, HC Wainwright initiated coverage on STML – StemlineTherapeutics (NASDAQ:STML) with a Buy with a price target of $38.00.
Some recent analyst ratings include
- 4/6/2018-HC Wainwright initiated coverage with a Buy rating.
- 10/31/2017-Cowen Reiterated Rating of Buy.
- 5/25/2017-Jefferies Group Reiterated Rating of Buy.
- 12/7/2016-Roth Capital Reiterated Rating of Buy.
Recent Insider Trading Activity For STML – StemlineTherapeutics (NASDAQ:STML)
STML – StemlineTherapeutics (NASDAQ:STML) has insider ownership of 16.70% and institutional ownership of 49.87%.
- On 3/13/2018 Kenneth Hoberman, COO, sold 29,987 with an average share price of $17.14 per share and the total transaction amounting to $513,977.18.
- On 3/12/2018 David Gionco, Insider, sold 9,183 with an average share price of $17.38 per share and the total transaction amounting to $159,600.54.
- On 3/12/2018 Ivan Bergstein, CEO, sold 37,857 with an average share price of $17.34 per share and the total transaction amounting to $656,440.38.
- On 3/7/2018 David Gionco, Insider, sold 1,413 with an average share price of $16.56 per share and the total transaction amounting to $23,399.28.
- On 3/7/2018 Ivan Bergstein, CEO, sold 6,797 with an average share price of $16.56 per share and the total transaction amounting to $112,558.32.
- On 3/7/2018 Kenneth Hoberman, COO, sold 3,027 with an average share price of $16.55 per share and the total transaction amounting to $50,096.85.
- On 2/27/2018 David Gionco, Insider, sold 8,984 with an average share price of $17.43 per share and the total transaction amounting to $156,591.12.
Recent Trading Activity for STML – StemlineTherapeutics (NASDAQ:STML)
Shares of STML – StemlineTherapeutics closed the previous trading session at 15.55 up +0.35 2.30% with shares trading hands.